Study Shows Medtronic (MDT) Microdebrider Turbinoplasty is a Significantly More Effective, Long-Term Treatment Than Coblation Radiofrequency for Nasal Obstructions
More News related to MDT
- Medtronic (MDT) Declares $0.205 Quarterly Dividend; 1.9% Yield
- Medtronic Board Approves Third Quarter Cash Dividend for Fiscal Year 2010
- Medtronic (MDT) Appoints Michael Coyle to EVP and Group President of Cardiology Business
- Medtronic Names Michael J. Coyle as Executive Vice President and Group President of Cardiology Businesses
- Association's Campaign Inspires Teens to Use CPR, AEDs to Save Lives
More News related to FDA
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
- Somaxon (SOMX) Volatile Into FDA Action Date
- Vivus (VVUS) Higher Ahead of Qnexa NDA
- Cardium (CXM) Subsidiary Files 510(k) with U.S. FDA for Excellagen Marketing Clearance
Medtronic (NYSE: MDT) announced that results of a study published in the February issue of the Laryngoscope were favorable toward the use of Medtronic's Straightshot(R) M4 Microdebrider for powered inferior turbinoplasty. Written by Liu et al from Taipei Medical University, "Microdebrider-Assisted Versus Radiofrequency-Assisted Turbinoplasty," states that patients treated with Medtronic's microdebrider experienced significantly better long-term outcomes than those who received treatment with a Coblation(R) radiofrequency device in what is the first three-year study directly comparing long-term efficacy of the two techniques.
"This study adds significant weight to the argument that RF treatments with Coblation aimed at the inferior turbinates are ineffective long term and put the patient's nasal mucosa at risk," says Scott Carpenter, senior product manager for ENT Powered Systems, part of the Surgical Technologies business at Medtronic.
See full press release here.
Sign up at EasyStockAlerts for free to see your stock news before it breaks to the rest of the public!
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
